Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770229 | 0.85 | HTR6 (0.34) | MEN1KMT2AHTR6ALDH1A1PKM | |
| SCHEMBL6199517 | 0.84 | HTR6 (0.38) | KMT2AHTR6ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL1600751 | 0.75 | ABCB1 (0.46) | KMT2AALDH1A1CYP3A4 | |
| SCHEMBL5772049 | 0.75 | ABCB1 (0.46) | KMT2AALDH1A1CYP3A4 | |
| SCHEMBL1602534 | 0.75 | ABCB1 (0.46) | KMT2AALDH1A1CYP3A4 | |
| SCHEMBL5774835 | 0.73 | HTT (0.30) | KMT2A | |
| SCHEMBL1602713 | 0.73 | ABCB1 (0.45) | KMT2A | |
| SCHEMBL1601307 | 0.73 | ABCB1 (0.45) | KMT2A | |
| SCHEMBL5771962 | 0.70 | MMP1 (0.34) | KMT2AHTR6ALDH1A1 | |
| SCHEMBL1603130 | 0.68 | ABCB1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MEN1 4418/4885KMT2A 864/4885HTR6 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.